Mydekla , daclatasvir, daclatasvir 60 mg, hepatitis c medicine


Read more

Mydekla 60 (Daclatasvir Dihydrocloride Tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

Product Description

MyDekla is demonstrated for use with sofosbuvir for the treatment &amp of patients with constant HCV genotype 3 contamination. Maintained virologic reaction (SVR) rates are decreased in HCV genotype 3-tainted patients with cirrhosis getting this regimen. Treatment with MyDacla ought to be started &amp and checked by a doctor experienced in the administration of unending hepatitis C.

Daclatasvir is one of the new direct-acting antiviral medications that objective distinctive strides of the hepatitis C infection (HCV) lifecycle. It is the first-since forever endorsed &amp HCV NS5A replication complex inhibitor, which means it meddles with a protein the infection uses to recreate.

Daclatasvir is demonstrated for use by grown-ups with unending hepatitis C, which means disease enduring over six months. It is endorsed for individuals with HCV genotype 1, 2, 3 or 4. Genotype 1 is the most widely recognized sort in Europe and considered the hardest to treat.

Daclatasvir can be utilized by individuals being dealt with for hepatitis C surprisingly (known as ‘treatment-innocent’) and for retreatment of individuals who were not cured with past interferon-based treatment (known as ‘treatment-experienced’).


Drug Name: Mydacla

Non specific Name: Daclatasvir Dihydrochloride

Organization Name: Mylan

Accessible as (Form and Strength): 60 mg tablets


There are no reviews yet.

Be the first to review “MyDekla”

Your email address will not be published. Required fields are marked *